Decibel Therapeutics (DBTX) announced the appointment of Matthew Kapusta to its Board of Directors. Matthew Kapusta has 25 years of experience in the life sciences industry and currently serves as Chief Executive Officer and Director of uniQure (QURE), a global gene therapy company.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on DBTX:
- Decibel Therapeutics Appoints Matthew Kapusta to its Board of Directors
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
- Decibel downgraded to Market Perform from Outperform at SVB Securities
- Decibel Therapeutics reports Q4 cash position $104.6M vs $162.3M last year
- Decibel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Update